Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1986 1
1988 1
1989 3
1990 3
1991 1
1994 1
1995 5
1996 3
1997 4
1998 4
1999 6
2000 7
2001 14
2002 8
2003 9
2004 11
2005 17
2006 14
2007 13
2008 17
2009 9
2010 11
2011 14
2012 14
2013 12
2014 7
2015 12
2016 10
2017 9
2018 4
2019 12
2020 6
2021 9
2022 13
2023 20
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

276 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial.
Taranto-Montemurro L, Messineo L, Sands SA, Azarbarzin A, Marques M, Edwards BA, Eckert DJ, White DP, Wellman A. Taranto-Montemurro L, et al. Am J Respir Crit Care Med. 2019 May 15;199(10):1267-1276. doi: 10.1164/rccm.201808-1493OC. Am J Respir Crit Care Med. 2019. PMID: 30395486 Free PMC article. Clinical Trial.
Objectives: We aimed to determine the effects of the combination of a norepinephrine reuptake inhibitor (atomoxetine) and an antimuscarinic (oxybutynin) on OSA severity (apnea-hypopnea index [AHI]; primary outcome) and genioglossus responsiveness (secondary outcome) in peo …
Objectives: We aimed to determine the effects of the combination of a norepinephrine reuptake inhibitor (atomoxetine) and an antimuscarinic …
Intravesical oxybutynin therapy for patients with neurogenic detrusor overactivity: a systematic review and meta-analysis.
Shen SH, Jia X, Peng L, Zeng X, Shen H, Luo DY. Shen SH, et al. Int Urol Nephrol. 2022 Apr;54(4):737-747. doi: 10.1007/s11255-022-03129-0. Epub 2022 Feb 28. Int Urol Nephrol. 2022. PMID: 35226282 Review.
PURPOSE: To evaluate the effectiveness and safety of intravesical oxybutynin therapy for patients with neurogenic detrusor overactivity. ...Nineteen studies were included for analysis, of which 392 patients including both adults and children were treated with intravesical …
PURPOSE: To evaluate the effectiveness and safety of intravesical oxybutynin therapy for patients with neurogenic detrusor overactivi …
Safety and efficacy of oxybutynin in patients with hyperhidrosis: systematic review and meta-analysis of randomized controlled trials.
El-Samahy M, Mouffokes A, Badawy MM, Amro S, Fayad T, Abdelwahab OA. El-Samahy M, et al. Arch Dermatol Res. 2023 Oct;315(8):2215-2226. doi: 10.1007/s00403-023-02587-5. Epub 2023 Mar 4. Arch Dermatol Res. 2023. PMID: 36869926 Free PMC article. Review.
RESULTS: Six studies were included in the meta-analysis, with a total of 293 patients. In all studies, patients were assigned to receive either Oxybutynin or Placebo. Oxybutynin represented an HDSS improvement (RR = 1.68 95% CI [1.21, 2.33], p = 0.002). ...CONCLUSIO …
RESULTS: Six studies were included in the meta-analysis, with a total of 293 patients. In all studies, patients were assigned to receive eit …
Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study.
Zorzitto ML, Holliday PJ, Jewett MA, Herschorn S, Fernie GR. Zorzitto ML, et al. Age Ageing. 1989 May;18(3):195-200. doi: 10.1093/ageing/18.3.195. Age Ageing. 1989. PMID: 2675580 Review.
Twenty-four incontinent elderly institutionalized subjects with detrusor instability participated in a double-blind placebo-controlled trial of oxybutynin chloride. Patients were randomly assigned to oral oxybutynin 5 mg or placebo twice daily. ...There were no clin …
Twenty-four incontinent elderly institutionalized subjects with detrusor instability participated in a double-blind placebo-controlled trial …
Impact of reboxetine plus oxybutynin treatment for obstructive sleep apnea on cardiovascular autonomic modulation.
Perger E, Castiglioni P, Faini A, Soranna D, Zambon A, Rosa D, Vicini S, Meriggi P, Pini L, Baratto C, Caravita S, Azarbarzin A, Parati G, Lombardi C. Perger E, et al. Sci Rep. 2023 Feb 23;13(1):3178. doi: 10.1038/s41598-023-29436-9. Sci Rep. 2023. PMID: 36823241 Free PMC article. Clinical Trial.
The combination of noradrenergic (reboxetine) plus antimuscarinic (oxybutynin) drugs (reb-oxy) reduced obstructive sleep apnea (OSA) severity but no data are available on its effects on cardiac autonomic modulation. ...OSA patients were randomized to a double-blind, crosso …
The combination of noradrenergic (reboxetine) plus antimuscarinic (oxybutynin) drugs (reb-oxy) reduced obstructive sleep apnea (OSA) …
Effect of oxybutynin and reboxetine on obstructive sleep apnea: a randomized, placebo-controlled, double-blind, crossover trial.
Berger M, Solelhac G, Marchi NA, Dussez R, Bradley B, Lecciso G, Heiniger G, Bayon V, Van Den Broecke S, Haba-Rubio J, Siclari F, Heinzer R. Berger M, et al. Sleep. 2023 Jul 11;46(7):zsad051. doi: 10.1093/sleep/zsad051. Sleep. 2023. PMID: 36861433 Clinical Trial.
The present study aimed to evaluate the effect of 1 week of 5 mg oxybutynin and 6 mg reboxetine (oxy-reb) on OSA versus placebo. METHODS: We performed a randomized, placebo-controlled, double-blind, crossover trial comparing the effect of 1 week of oxy-reb versus 1 week of …
The present study aimed to evaluate the effect of 1 week of 5 mg oxybutynin and 6 mg reboxetine (oxy-reb) on OSA versus placebo. METH …
Mirabegron as effective as oxybutynin for ureteral stent symptoms.
Jaworski P, Mello GF, Ferreira GM, Oliveira MH, Fraga R. Jaworski P, et al. Rev Assoc Med Bras (1992). 2021 Dec;67(12):1793-1797. doi: 10.1590/1806-9282.20210711. Rev Assoc Med Bras (1992). 2021. PMID: 34909951 Free article. Clinical Trial.
This study aimed to compare the effect of mirabegron with oxybutynin in relieving ureteral stent-related symptoms over time. METHODS: A prospective, longitudinal, randomized, single-blinded study was conducted. ...A longitudinal analysis showed that global quality of life …
This study aimed to compare the effect of mirabegron with oxybutynin in relieving ureteral stent-related symptoms over time. METHODS: …
Oxybutynin gel versus nanoemulgel for treating primary palmar hyperhidrosis: A pilot double-blind randomized controlled trial.
Saki N, Shakouri N, Rastaghi F, Hosseini SA, Alipour S, Ahramiyanpour N. Saki N, et al. J Cosmet Dermatol. 2023 Aug;22(8):2268-2272. doi: 10.1111/jocd.15715. Epub 2023 Mar 31. J Cosmet Dermatol. 2023. PMID: 36999480 Clinical Trial.
In two randomly allocated groups of 15, patients diagnosed with primary palmar hyperhidrosis by an attending dermatologist applied half a fingertip (roughly 0.25 g) of 1% oxybutynin topical gel or 1% oxybutynin nanoemulgel to both palms every 12 h for one month. ... …
In two randomly allocated groups of 15, patients diagnosed with primary palmar hyperhidrosis by an attending dermatologist applied half a fi …
The combination of atomoxetine and oxybutynin for the treatment of obstructive sleep apnea in children with Down syndrome.
Combs D, Edgin J, Hsu CH, Bottrill K, Van Vorce H, Gerken B, Matloff D, La Rue S, Parthasarathy S. Combs D, et al. J Clin Sleep Med. 2023 Dec 1;19(12):2065-2073. doi: 10.5664/jcsm.10764. J Clin Sleep Med. 2023. PMID: 37555595 Clinical Trial.
Participants received low-dose ato-oxy (0.5 mg/kg atomoxetine and 5 mg oxybutynin) and high-dose ato-oxy (1.2 mg/kg atomoxetine and 5 mg oxybutynin) for 1 month in random order. ...CITATION: Combs D, Edgin J, Hsu C-H, et al. The combination of atomoxetine and oxy …
Participants received low-dose ato-oxy (0.5 mg/kg atomoxetine and 5 mg oxybutynin) and high-dose ato-oxy (1.2 mg/kg atomoxetine and 5 …
Reboxetine Plus Oxybutynin for OSA Treatment: A 1-Week, Randomized, Placebo-Controlled, Double-Blind Crossover Trial.
Perger E, Taranto Montemurro L, Rosa D, Vicini S, Marconi M, Zanotti L, Meriggi P, Azarbarzin A, Sands SA, Wellman A, Lombardi C, Parati G. Perger E, et al. Chest. 2022 Jan;161(1):237-247. doi: 10.1016/j.chest.2021.08.080. Epub 2021 Sep 20. Chest. 2022. PMID: 34543665 Free PMC article. Clinical Trial.
BACKGROUND: The recent discovery that a combination of noradrenergic and antimuscarinic drugs improved upper airway muscle function during sleep and reduced OSA severity has revitalized interest in pharmacologic therapies for OSA. RESEARCH QUESTION: Would 1 week of reboxetine plu …
BACKGROUND: The recent discovery that a combination of noradrenergic and antimuscarinic drugs improved upper airway muscle function during s …
276 results

Searches related to "oxybutynin"